C-CAMP AMR Quest 2020
Objective of the Quest
To Identify and reward innovative ideas and solutions in the AMR domain and present opportunities for development and commercialization of these.
Scope of Application
The Antimicrobial Resistance Quest 2020 is inviting applications in the AMR domain spanning:
- Non-traditional therapeutics including the indirect acting small molecules (virulence, potentiators, BLI combinations, etc), Direct- and indirect-acting large molecules (peptides, etc.), phage, microbiome, nucleic acid, anti-sense, Drug conjugates (ADC, other dual acting drug conjugates)
- Preventatives including vaccines, preventative antibodies and fragments, and microbiome products.
- Diagnostics including devices which can diagnose ID/AST of pathogens
- Direct acting small molecule therapeutics including new classes of drugs or new targets only
* All applications need to be related to development of products, not basic research
Exciting Rewards *
- Acceptance into 3-month C-CAMP AMR Accelerator Program and evaluation of funding opportunities by CARB-X
- Participation in any one of the following International Conferences/Programs, with all costs covered:
o iCARE, International Course on Antibiotics and Resistance, held at Institut Pasteur, Les Pensières, Annecy, France
o EU AMR Innovations Mission, UK held in England from 26 October to 30 October
o Emerging Antimicrobials and Diagnostics in AMR 2020 held in Amsterdam, 18 Nov to 19 Nov
o World Health Summit, Berlin, Germany from October 25 to 27
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.